0

BML-210

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP537034176
CAS537034-17-6
Structure
MDL NumberMFCD08062139
Molecular Weight339.43
InChI KeyRFLHBLWLFUFFDZ-UHFFFAOYSA-N
Description≥98% (HPLC), powder
SolubilityDMSO: >20 mg/mL
Assay≥98% (HPLC)
Colorwhite to very faintly yellow
Formpowder
Size5MG, 25MG
Storage Conditions2-8°C
1

Histone Deacetylase Inhibitor BML-210 Induces Growth Inhibition and Apoptosis and Regulates HDAC and DAPC Complex Expression Levels in Cervical Cancer Cells

Veronika V Borutinskaite, Karl-Eric Magnusson, Ruta Navakauskiene

Mol Biol Rep. 2012 Dec;39(12):10179-86.

PMID: 23007576

1

Proteomic Analyses of Sirt1-mediated Cisplatin Resistance in OSCC Cell Line

Ping Xiong, Yu-xuan Li, Yun-tao Tang, Hong-gang Chen

Protein J. 2011 Oct;30(7):499-508.

PMID: 21947960

1

Retinoic Acid and Histone Deacetylase Inhibitor BML-210 Inhibit Proliferation of Human Cervical Cancer HeLa Cells

Veronika V Borutinskaite, Ruta Navakauskiene, Karl-Eric Magnusson

Ann N Y Acad Sci. 2006 Dec;1091:346-55.

PMID: 17341627

1

The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming

Veronika Borutinskaitė, Rūta Navakauskienė

Int J Mol Sci. 2015 Aug 6;16(8):18252-69.

PMID: 26287160

1

The Novel Histone Deacetylase Inhibitor BML-210 Exerts Growth Inhibitory, Proapoptotic and Differentiation Stimulating Effects on the Human Leukemia Cell Lines

Jurate Savickiene, Veronika-Viktorija Borutinskaite, Grazina Treigyte, Karl-Eric Magnusson, Ruta Navakauskiene

Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18.

PMID: 16978604

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode